Detection of prostate cancer
Detection of prostate cancer
复制标题
前列腺癌的检测
DOI：
--
复制
发表时间：
1995
影响因子：
--
通讯作者：
Fritz H Schroder
中科院分区：
文献类型：
--
作者：
Fritz H Schroder
筛查整个人群还没有被证明是值得的，
1994年8月，美国食品和药物管理局批准了一项用于检测前列腺癌的血液测试。建议前列腺特异性抗原的Hybritech Tandem检测与直肠指检联合使用。这一决定是基于检测研究的数据，但主要是基于加泰罗尼亚等人最近在六个不同中心对6630名男性进行的一项研究。1显然，当使用这种测试组合时，前列腺癌可以更早、更高地被检测到。研究小组得出结论，“大多数前列腺癌在首次使用传统检测方法（直肠指检）诊断时已经扩散到腺体之外。由于目前或在可预见的未来没有晚期前列腺癌的治愈性治疗，改善患者预后的最有希望的替代方案是加强早期检测。该报告继续声称，该测试提高了对局限于腺体的前列腺癌的检测，比传统的直肠检查提高了78%。在114名接受根治性前列腺切除术的男性中，局限于前列腺的癌症比例为71%，这是对早期研究的重要改进，如货车den Ouden等人的研究。
Screening the whole population has not yet been shown to be worth while
In August 1994 the United States Food and Drug Administration approved a blood test for use in detecting cancer of the prostate. The Hybritech Tandem assays for prostate specific antigen were recommended for use in combination with digital rectal examination. The decision was based on data from detection studies—but mainly on a recent study of 6630 men carried out in six different centres by Catalona et al.1 Clearly prostate cancer can be detected earlier and at a higher rate when this combination of tests is used. The study group concluded that “the majority of prostate cancers have spread beyond the gland when first diagnosed using the conventional detection method, digital rectal examination. With no curative therapy for advanced prostate cancer available currently or in the foreseeable future, the most promising alternative for improving the prognosis of patients is to enhance early detection.” The report went on to claim that the test improved the detection of prostate cancer confined to the gland by as much as 78% over conventional rectal examination. The proportion of cancers confined to the prostate in the 114 men who underwent surgical treatment by radical prostatectomy was 71%—an important improvement over earlier studies such as that by Van den Ouden et …